title: [Iliopsoas abscess: therapeutic approach and outcome in a series of 35 patients].
abstract: BACKGROUND
  The present study was aimed at reviewing the iliopsoas abscess (IPA) from a contemporary perspective, on the basis of experience from two tertiary referral centres.
  
  
  METHODS
  We performed a retrospective analysis of 35 cases of IPA diagnosed between 1998 and 2009. Their clinical and microbiological features were recorded, as well as their long-term outcome according to the type of treatment: antibiotics alone (10 patients), or antibiotics plus percutaneous drainage or surgery (25 patients).
  
  
  RESULTS
  Primary abscess occurred in 8 patients. The most frequent source of secondary abscesses was spondylodiscitis. The classic clinical triad (fever, pain and functional impairment) was present in 10 patients, with a median duration of symptoms before diagnosis of 12 days. Staphylococcus aureus was the most frequently isolated microorganism. At the end of a median follow-up of 454 days, the risk of poor outcome (related death and/or relapse) was higher among patients with diabetes mellitus (44.4% vs. 7.7%; P=.027), with no significant differences according to the therapeutic approach (20.0% in the group of antibiotics alone vs. 28.0% in the group with drainage or surgery).
  
  
  CONCLUSIONS
  In our series, most cases of IPA were due to S. aureus and secondary to a skeletal source. Antibiotic therapy seems effective in the long-term, although diabetic patients had a higher risk of relapse.
authors.affiliation: Unidad de Enfermedades Infecciosas, Hospital Universitario 12 de Octubre, Universidad Complutense, Madrid, España. mario_fdezruiz@yahoo.es
authors.forename: Mario
authors.initials: M
authors.lastname: Fernández-Ruiz
authors.forename: Miriam
authors.initials: M
authors.lastname: Estébanez-Muñoz
authors.forename: Francisco
authors.initials: F
authors.lastname: López-Medrano
authors.forename: José María
authors.initials: JM
authors.lastname: Aguado
mesh_terms: D000328:Adult; D000368:Aged; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D003131:Combined Modality Therapy; D015897:Comorbidity; D048909:Diabetes Complications / Q000188:drug therapy / Q000453:epidemiology / Q000382:microbiology / Q000601:surgery; D015299:Discitis / Q000150:complications / Q000382:microbiology; D004322:Drainage; D004756:Enterobacteriaceae Infections / Q000188:drug therapy / Q000453:epidemiology / Q000601:surgery; D005260:Female; D006785:Hospitals, University / Q000706:statistics & numerical data; D006801:Humans; D008103:Liver Cirrhosis / Q000150:complications / Q000453:epidemiology; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D016659:Psoas Abscess / Q000188:drug therapy / Q000453:epidemiology / Q000382:microbiology / Q000601:surgery / Q000628:therapy*; D012008:Recurrence; D012189:Retrospective Studies; D013030:Spain / Q000453:epidemiology; D013203:Staphylococcal Infections / Q000188:drug therapy / Q000453:epidemiology / Q000601:surgery; D016896:Treatment Outcome
chemical_list: D000900:Anti-Bacterial Agents